GBT Announces New Employment Inducement Grants
May 04 2018 - 8:30AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced
that on May 1, 2018, the compensation committee of the Company’s
board of directors granted four new employees options to purchase
an aggregate of 14,250 shares of the Company’s common stock with a
per share exercise price of $45.20, the closing trading price on
the grant date, and restricted stock units for an aggregate of
9,400 shares of the Company’s common stock. All of the
above-described awards were made under the Company’s 2017
Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement
material to the employees entering into employment with the Company
in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted
pursuant to the terms of the Plan. The Company has reserved an
aggregate of 300,000 shares of its common stock (including the
shares underlying the stock option and restricted stock unit award
described above) for issuance under the Plan, which was approved by
the Company’s board of directors in January 2017.
About GBTGBT is a clinical-stage
biopharmaceutical company determined to discover, develop and
deliver innovative treatments that provide hope to underserved
patient communities. GBT is developing its lead product candidate,
voxelotor, as an oral, once-daily therapy for sickle cell disease.
To learn more, please visit www.gbt.com and follow the company on
Twitter @GBT_news.
Contact Information: Myesha Lacy
(investors)GBT650-351-4730investor@gbt.com
Julie Normart (media)W2O pure415-946-1087media@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024